As a PROTAC molecule capable of targeting the BRD4 protein in TNBC, dBET6 exhibits anti-tumor properties and holds promise for overcoming resistance to traditional chemotherapy drugs in TNBC. This evidence concerns the gene BRD4 and neoplasm.